The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
COVID-19Breakthrough Infection
Interventions
BIOLOGICAL

BNT162b2

BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.

BIOLOGICAL

mRNA-1273

mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.

BIOLOGICAL

MVC-COV1901

MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan

Sponsors
All Listed Sponsors
collaborator

Medigen Vaccine Biologics Corp.

INDUSTRY

lead

Chang Gung Memorial Hospital

OTHER

NCT05132855 - The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine | Biotech Hunter | Biotech Hunter